Jared Gollob, Chief Medical Officer at Kymera Therapeutics, Inc. (KYMR), sold 79,200 shares at $45.59 ($3.6M) on 2024-07-16, disclosed to the SEC on 2024-07-16.
Scheduled sale ($3.6M) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.15 | 16,455 | $743K | 20.6% |
| 2 | $45.15 | 16,455 | $743K | 20.6% |
| 3 | $45.59 | 13,281 | $605K | 16.8% |
| 4 | $45.59 | 13,281 | $605K | 16.8% |
| 5 | $46.10 | 9,864 | $455K | 12.6% |
| 6 | $46.10 | 9,864 |
| $455K |
| 12.6% |
| Total | $45.53 avg | 79,200 | $3.6M | 100% |
| Filing → |
| KYMR | SELL | 2025-10-15 | $7.3M | — | Filing → |
| KYMR | SELL | 2025-10-14 | $187K | — | Filing → |
| KYMR | SELL | 2025-03-03 | $317K | — | Filing → |